Navigation Links
Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta

ATLANTA, April 26, 2012 /PRNewswire/ -- Elekta, a leading international technology and solutions provider for the treatment of cancer and brain disorders, is relocating its North America headquarters in 2012. Elekta's new HQ will be The Terraces in Atlanta's Central Perimeter business district. The company anticipates adding more than 100 new jobs over five years in the life sciences field, specifically in the medical device and healthcare IT sectors.

"Elekta's global influence in healthcare is increasing rapidly," says Elekta's President and CEO, Tomas Puusepp. "The move of our North America headquarters to Atlanta will support this trend and strengthen Atlanta's growing biomedical community."

Elekta will be a new asset in DeKalb County, according to Judy Turner, Chair, Development Authority of DeKalb County, Ga.

"Elekta is the type of innovative health care company that will add to the synergy of other life science assets already located in DeKalb County, such as the Centers for Disease Control and Emory Healthcare," she says. "The Development Authority of DeKalb County is very proud to be a partner with Elekta and is looking forward to their new facility in DeKalb County."

"Medical device companies such as Elekta represent a large proportion of our bioscience industry, so we're pleased Elekta has chosen to continue to grow and create jobs in Georgia," adds Chris Cummiskey, Commissioner of the Georgia Department of Economic Development. "We have terrific collaborations and research expertise in this area."

Elekta helps reinforce the fact that Atlanta is a leading location for international bioscience companies, according to Hans Gant, senior vice president of economic development for the Metro Atlanta Chamber.

"One of Atlanta's true strengths is having access to a highly talented workforce, which will help support the projected growth of Elekta's operations," he says.

"The expansion of Elekta's North American Headquarters is an excellent example of the partnership between the Georgia Department of Economic Development, Metro Atlanta Chamber, and the City of Dunwoody to cultivate new business for Georgia," said Economic Development Director Michael Starling. "Elekta is a true reflection of the state's and Dunwoody's strategy to recruit and grow world-class technology companies."

"The decision by Elekta to establish its North American headquarters in Dunwoody is the culmination of a truly collaborative and creative effort," said Jeff Estep, executive managing director of Newmark Knight Frank, the consultant to Elekta. "We conducted a thorough analysis of Elekta's needs and location options across North America, including in-depth review of business costs, talent availability, training and operational processes, and the Atlanta area proved itself to be the ideal location for the company's global growth objectives. We received incredible support from the State of Georgia, DeKalb County, the City of Dunwoody and the Metro Atlanta Chamber."

Elekta develops sophisticated tools and dose planning systems for radiation therapy and radiosurgery and brachytherapy, in addition to software systems that improve the efficiency of workflows throughout the spectrum of cancer care. Among its most recognized products are Elekta Synergy®, Elekta Infinity™ and Elekta Axesse™ radiation treatment systems (linear accelerators), Leksell Gamma Knife® Perfexion™ radiosurgery system for ultra-precise treatment of intracranial disease targets, MOSAIQ® oncology information system and Monaco® treatment planning system.

Employing about 3,300 people globally, Elekta markets its solutions in North and South America, Europe, the Middle East, Africa and Asia-Pacific countries.

For further information, please contact:

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email:
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email:
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website:

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
2. NJ-Based Surgeon Helps Pioneer Dramatic Advance in Treating Damaged Discs
3. Stem Cell Pioneer to Speak to A.L.L. Personhood Conference
4. Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
5. Pioneering Brain Malformation Treatment Performed Using Novalis Tx(TM) Radiosurgery Technology in India
6. Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health
7. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
8. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
9. Pioneer(R) Surgical Technology, Inc. Announces New Expansion Plan
10. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
11. Pioneer(R) Surgical Technology, Inc. and Bonovo(R) Orthopedics, Inc. Establish Foothold in Fastest Growing Spine Market in the World
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):